Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan

Ikeda, Sayaka; Ueda, Yutaka; Yagi, Asami; Mizushima, Taichi; Sukegawa, Akiko; Kudoh, Risa; Yamaguchi, Manako; Kurosawa, Megumi; Miyagi, Etsuko; Sekine, Masayuki; Enomoto, Takayuki

doi:https://doi.org/10.1111/cas.16375

Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan

Ikeda, Sayaka; Ueda, Yutaka; Yagi, Asami et al.

Cancer Science, 2024, 116(1), 226-232

Number of Access:1,278（2025-08-13 22:43 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/98885

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
CancerSci_cas.16375	pdf	None	350 KB	40	2024.12.26

Creative Commons : Attribution - NonCommercial

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan
Creator	NRID 1000040818902 1000040818902 CreatorName Ikeda, Sayaka
	NRID 1000010346215 1000010346215 ORCID 0000-0001-8760-6379 0000-0001-8760-6379 researchmap permalink read0092318 read0092318 Scopus Author ID 55087087500 55087087500 CreatorName Ueda, Yutaka
	NRID 1000030793450 1000030793450 researchmap permalink 2018101510006244 2018101510006244 Scopus Author ID 56244059700 56244059700 CreatorName Yagi, Asami
	NRID 1000080835059 1000080835059 CreatorName Mizushima, Taichi
	NRID 1000030347322 1000030347322 CreatorName Sukegawa, Akiko
	NRID 1000030752787 1000030752787 CreatorName Kudoh, Risa
	CreatorName Yamaguchi, Manako
	CreatorName Kurosawa, Megumi
	NRID 1000040275053 1000040275053 CreatorName Miyagi, Etsuko
	NRID 1000070345502 1000070345502 CreatorName Sekine, Masayuki
	NRID 1000090283754 1000090283754 ORCID 0000-0003-4538-5541 0000-0003-4538-5541 researchmap permalink Takayuki1956 Takayuki1956 CreatorName Enomoto, Takayuki
Subject	case–control studies
	human papillomavirus viruses
	papillomavirus vaccines
	uterine cervical dysplasia
	vaccine efficacy
Description	Ikeda S., Ueda Y., Yagi A., et al. Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan. Cancer Science, (2024); https://doi.org/10.1111/cas.16375.
Abstract	An increase in cervical cancer incidence has been reported in Japan. The Ministry of Health, Labor, and Welfare of Japan has resumed the active recommendation of regular HPV vaccines in 2022. In Japan, the preventive effect of CIN3+ in the real world has not yet been demonstrated in age-adjusted cohort or case–control studies. This study aimed to estimate the effect of the HPV vaccine against CIN3+ in Japanese women. This nationwide case–control study from April 2013 to March 2020 targeted women aged 20–26 years old at the time of cervical screening. We compared HPV vaccination exposure between those with abnormal and those with normal cytology. Abnormal cytology was classified into cervical intraepithelial neoplasia (CIN)1+, CIN2+, and CIN3+. We calculated the odds ratio (OR) and 95% confidence interval (CI) of the above endpoints and vaccination exposure using the conditional logistic regression model and estimated vaccine effectiveness using the formula (1 −OR) × 100. A total of 2790 cases and 13,990 controls (one-to-five matching) were eligible in 37 municipalities in Japan. In this study, 61 CIN3 (2.2%) and 10 squamous cell carcinomas (SCC) (0.4%) were found. The OR for CIN3+ versus controls was 0.14 (95% CI, 0.03–0.75), equating to a vaccine effectiveness of 86%. Of the 10 patients who had SCC none were vaccinated. This nationwide case–control study in Japan demonstrated a substantial risk reduction in CIN3+ among women who did versus those who did not receive HPV vaccination.
Publisher	John Wiley and Sons Inc
Source Title	Cancer Science
Volume (Issue)	116(1)
Page	226-232
Date of Issued	2024-10-25
Language	English
Handle URL	https://hdl.handle.net/11094/98885
PISSN	13479032
eISSN	13497006
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1111/cas.16375
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCTERMS.bibliographicCitation	Cancer Science. 2024, 116(1), p. 226-232
DC.title	Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan
DC.creator	Ikeda, Sayaka
	Ueda, Yutaka
	Yagi, Asami
	Mizushima, Taichi
	Sukegawa, Akiko
	Kudoh, Risa
	Yamaguchi, Manako
	Kurosawa, Megumi
	Miyagi, Etsuko
	Sekine, Masayuki
	Enomoto, Takayuki
DC.publisher	John Wiley and Sons Inc
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-10-25
DC.identifier	https://doi.org/10.1111/cas.16375
DC.subject	case–control studies
	human papillomavirus viruses
	papillomavirus vaccines
	uterine cervical dysplasia
	vaccine efficacy
DC.description	Ikeda S., Ueda Y., Yagi A., et al. Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan. Cancer Science, (2024); https://doi.org/10.1111/cas.16375.
DCTERMS.abstract	An increase in cervical cancer incidence has been reported in Japan. The Ministry of Health, Labor, and Welfare of Japan has resumed the active recommendation of regular HPV vaccines in 2022. In Japan, the preventive effect of CIN3+ in the real world has not yet been demonstrated in age-adjusted cohort or case–control studies. This study aimed to estimate the effect of the HPV vaccine against CIN3+ in Japanese women. This nationwide case–control study from April 2013 to March 2020 targeted women aged 20–26 years old at the time of cervical screening. We compared HPV vaccination exposure between those with abnormal and those with normal cytology. Abnormal cytology was classified into cervical intraepithelial neoplasia (CIN)1+, CIN2+, and CIN3+. We calculated the odds ratio (OR) and 95% confidence interval (CI) of the above endpoints and vaccination exposure using the conditional logistic regression model and estimated vaccine effectiveness using the formula (1 −OR) × 100. A total of 2790 cases and 13,990 controls (one-to-five matching) were eligible in 37 municipalities in Japan. In this study, 61 CIN3 (2.2%) and 10 squamous cell carcinomas (SCC) (0.4%) were found. The OR for CIN3+ versus controls was 0.14 (95% CI, 0.03–0.75), equating to a vaccine effectiveness of 86%. Of the 10 patients who had SCC none were vaccinated. This nationwide case–control study in Japan demonstrated a substantial risk reduction in CIN3+ among women who did versus those who did not receive HPV vaccination.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	98885
citation_title	Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan
citation_author	Ikeda, Sayaka
	Ueda, Yutaka
	Yagi, Asami
	Mizushima, Taichi
	Sukegawa, Akiko
	Kudoh, Risa
	Yamaguchi, Manako
	Kurosawa, Megumi
	Miyagi, Etsuko
	Sekine, Masayuki
	Enomoto, Takayuki
citation_publisher	John Wiley and Sons Inc
citation_language	English
citation_date	2024-10-25
citation_journal_title	Cancer Science
citation_volume	116
citation_issue	1
citation_firstpage	226
citation_lastpage	232
citation_doi	https://doi.org/10.1111/cas.16375
citation_public_url	https://hdl.handle.net/11094/98885

Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case–control study in Japan

Link to primary information

Item Information

Show details